334 related articles for article (PubMed ID: 22142827)
1. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Innocenti F; Owzar K; Cox NL; Evans P; Kubo M; Zembutsu H; Jiang C; Hollis D; Mushiroda T; Li L; Friedman P; Wang L; Glubb D; Hurwitz H; Giacomini KM; McLeod HL; Goldberg RM; Schilsky RL; Kindler HL; Nakamura Y; Ratain MJ
Clin Cancer Res; 2012 Jan; 18(2):577-84. PubMed ID: 22142827
[TBL] [Abstract][Full Text] [Related]
2. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Innocenti F; Owzar K; Jiang C; Etheridge AS; Gordân R; Sibley AB; Mulkey F; Niedzwiecki D; Glubb D; Neel N; Talamonti MS; Bentrem DJ; Seiser E; Yeh JJ; Van Loon K; McLeod H; Ratain MJ; Kindler HL; Venook AP; Nakamura Y; Kubo M; Petersen GM; Bamlet WR; McWilliams RR
PLoS One; 2018; 13(8):e0202272. PubMed ID: 30107003
[TBL] [Abstract][Full Text] [Related]
3. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
5. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1.
Sato Y; Ueno H; Ioka T; Ohkawa S; Ikeda M; Shimamura T; Tsuji A; Tsuchiya Y; Furuse J; Ishii H; Furuya K; Iguchi H; Saito Y; Kaniwa N; Sawada JI; Sakamoto H; Sekine A; Okusaka T; Yoshida T;
Pancreas; 2018; 47(5):637-642. PubMed ID: 29683977
[TBL] [Abstract][Full Text] [Related]
6. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
7. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
8. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Romanus D; Kindler HL; Archer L; Basch E; Niedzwiecki D; Weeks J; Schrag D;
J Pain Symptom Manage; 2012 Feb; 43(2):205-17. PubMed ID: 22104618
[TBL] [Abstract][Full Text] [Related]
9. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
Yamaue H; Tsunoda T; Tani M; Miyazawa M; Yamao K; Mizuno N; Okusaka T; Ueno H; Boku N; Fukutomi A; Ishii H; Ohkawa S; Furukawa M; Maguchi H; Ikeda M; Togashi Y; Nishio K; Ohashi Y
Cancer Sci; 2015 Jul; 106(7):883-90. PubMed ID: 25867139
[TBL] [Abstract][Full Text] [Related]
11. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
[TBL] [Abstract][Full Text] [Related]
12. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
13. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Xie H; Jiang W; Xiao SY; Liu X
J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
[TBL] [Abstract][Full Text] [Related]
14. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide association study of survival in patients with pancreatic adenocarcinoma.
Wu C; Kraft P; Stolzenberg-Solomon R; Steplowski E; Brotzman M; Xu M; Mudgal P; Amundadottir L; Arslan AA; Bueno-de-Mesquita HB; Gross M; Helzlsouer K; Jacobs EJ; Kooperberg C; Petersen GM; Zheng W; Albanes D; Boutron-Ruault MC; Buring JE; Canzian F; Cao G; Duell EJ; Elena JW; Gaziano JM; Giovannucci EL; Hallmans G; Hutchinson A; Hunter DJ; Jenab M; Jiang G; Khaw KT; LaCroix A; Li Z; Mendelsohn JB; Panico S; Patel AV; Qian ZR; Riboli E; Sesso H; Shen H; Shu XO; Tjonneland A; Tobias GS; Trichopoulos D; Virtamo J; Visvanathan K; Wactawski-Wende J; Wang C; Yu K; Zeleniuch-Jacquotte A; Chanock S; Hoover R; Hartge P; Fuchs CS; Lin D; Wolpin BM
Gut; 2014 Jan; 63(1):152-60. PubMed ID: 23180869
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.
Li D; Frazier M; Evans DB; Hess KR; Crane CH; Jiao L; Abbruzzese JL
J Clin Oncol; 2006 Apr; 24(11):1720-8. PubMed ID: 16520463
[TBL] [Abstract][Full Text] [Related]
17. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Innocenti F; Jiang C; Sibley AB; Denning S; Etheridge AS; Watson D; Niedzwiecki D; Hatch AJ; Hurwitz HI; Nixon AB; Furukawa Y; Kubo M; Crona DJ; Kindler HL; McLeod HL; Ratain MJ; Owzar K
Pharmacogenet Genomics; 2019 Aug; 29(6):123-131. PubMed ID: 30889042
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Xie H; Lin J; Thomas DG; Jiang W; Liu X
Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
Richards DA; Boehm KA; Waterhouse DM; Wagener DJ; Krishnamurthi SS; Rosemurgy A; Grove W; Macdonald K; Gulyas S; Clark M; Dasse KD
Ann Oncol; 2006 Jul; 17(7):1096-102. PubMed ID: 16641168
[TBL] [Abstract][Full Text] [Related]
20. [Prognosis of pancreatic adenocarcinoma].
Escourrou J; Buscail L; Pages P; Moreau J; Faure P
Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C30-3. PubMed ID: 11787377
[No Abstract] [Full Text] [Related]
[Next] [New Search]
